Activation of c-Met initiates downstream intracellular cascades that govern cell survival, motogenesis, and dendritic spinogenesis
At PSPeptides, every product is available to every buyer from the first order
Published human evidence includes topical applications over defined periods, diabetic-ulcer wound protocols, and a registered topical acute-wound trial, while there is no FDA-approved injectable GHK-Cu label that establishes a standard dose [2], [3], [7], [8]
Respected were the beneficial effects obtained with free peptides or peptides with different carriers
Unlike a stimulant, it does not produce a same-day effect the published trials titrated the dose upward over weeks and measured their primary weight endpoints at 26 weeks (Phase 2) and 68 weeks (Phase 3)